Tycel Phillips is a Hematology physician affiliated with City Of Hope National Medical Center. OpenAlex indexes 357 publications with 4,307 citations (h-index 34); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 Duarte Rd
Duarte, CA 910103012
Telephone
626-256-4673Provider last certified this registry record 4 May 2022.
Clinical trials
- Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Sponsor: City of Hope Medical Center
- Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Sponsor: City of Hope Medical Center
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Sponsor: City of Hope Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
30 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year202511 payments$10,548openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20253 payments$10,311openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
42.1%Kinase inhibitor23.9%Brukinsa100%Part D<11 patientsThalidomide Analog18.2%Revlimid100%Part D<11 patientsDermatology
17.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor17.6%Acyclovir100%Part D≥12 patientsMetabolism & gastrointestinal
13.2%Corticosteroid13.2%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- Protocol Review and Monitoring System
Beckman Research Institute/city of Hope
FY2026$222,905P30CA033572
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Yuman Fong, MD
City Of Hope National Medical Center
Ravi Salgia, MD, PhD
City Of Hope National Medical Center
Stephen Gruber, MD
City Of Hope National Medical Center
Tanya Siddiqi, MD
City Of Hope National Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”